Chronic hepatitis C – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chronic hepatitis C – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing bemnifosbuvir-ruzasvir and sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in adult patients https://clinicaltrials.eu/trial/comparing-bemnifosbuvir-ruzasvir-and-sofosbuvir-velpatasvir-for-treatment-of-chronic-hepatitis-c-virus-infection-in-adult-patients/ Wed, 29 Apr 2026 15:06:51 +0000 https://clinicaltrials.eu/trial/comparing-bemnifosbuvir-ruzasvir-and-sofosbuvir-velpatasvir-for-treatment-of-chronic-hepatitis-c-virus-infection-in-adult-patients/ This study focuses on treating people with Chronic Hepatitis C Virus Infection, a long-term liver condition caused by the hepatitis C virus. The study compares two different combination treatments: Bemnifosbuvir-Ruzasvir (also known as BEM/RZR) and Sofosbuvir-Velpatasvir (also known as SOF/VEL). Both treatments are taken as tablets by mouth.

The purpose is to determine if BEM/RZR treatment, given once daily for either 8 or 12 weeks, works as well as SOF/VEL treatment, which is given once daily for 12 weeks. These medications work by directly targeting the virus that causes the infection.

During the study, participants will receive one of these treatments and will have their virus levels monitored through blood tests. The study will track how well the medications clear the virus from the body and whether the infection returns after treatment ends. The total duration of monitoring for each participant extends to 24 weeks to ensure long-term effectiveness of the treatment.

]]> Study on the Safety and Effectiveness of Bemnifosbuvir and Ruzasvir for Patients with Chronic Hepatitis C https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bemnifosbuvir-and-ruzasvir-for-patients-with-chronic-hepatitis-c/ Wed, 29 Apr 2026 14:23:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bemnifosbuvir-and-ruzasvir-for-patients-with-chronic-hepatitis-c/ This clinical trial is focused on studying the treatment of Chronic Hepatitis C Virus (HCV) Infection, a long-lasting viral infection that affects the liver. The study will use two medications: Bemnifosbuvir Hemisulfate, also known as BEM, which is taken in tablet form, and Ruzasvir, also known as RZR, which is taken in capsule form. Both medications are antivirals, meaning they are designed to fight viruses in the body.

The purpose of the study is to evaluate the safety and effectiveness of these medications when used together. Participants will take the medications for a period of up to eight weeks. After completing the treatment, the study will continue to monitor participants for an additional 12 weeks to see if the virus remains undetectable in their blood, which is referred to as a sustained virologic response.

Throughout the study, participants will be regularly checked to ensure the treatment is safe and to observe how well it works in reducing the virus. The study aims to provide valuable information on whether this combination of medications can be a successful treatment option for people with chronic HCV infection.

]]>